Tango Therapeutics (TNGX) Gains from Sales and Divestitures (2020 - 2025)
Historic Gains from Sales and Divestitures for Tango Therapeutics (TNGX) over the last 5 years, with Q3 2025 value amounting to $454414.0.
- Tango Therapeutics' Gains from Sales and Divestitures rose 7952.8% to $454414.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $454414.0, marking a year-over-year increase of 7952.8%. This contributed to the annual value of $260865.0 for FY2024, which is 59564.0% up from last year.
- Tango Therapeutics' Gains from Sales and Divestitures amounted to $454414.0 in Q3 2025, which was up 7952.8% from $433483.0 recorded in Q2 2025.
- Over the past 5 years, Tango Therapeutics' Gains from Sales and Divestitures peaked at $454414.0 during Q3 2025, and registered a low of $37500.0 during Q2 2023.
- Over the past 4 years, Tango Therapeutics' median Gains from Sales and Divestitures value was $254750.5 (recorded in 2021), while the average stood at $236270.1.
- Per our database at Business Quant, Tango Therapeutics' Gains from Sales and Divestitures tumbled by 6744.62% in 2021 and then surged by 59564.0% in 2024.
- Tango Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $256598.0 in 2021, then plummeted by 85.39% to $37500.0 in 2023, then surged by 595.64% to $260865.0 in 2024, then skyrocketed by 74.2% to $454414.0 in 2025.
- Its Gains from Sales and Divestitures was $454414.0 in Q3 2025, compared to $433483.0 in Q2 2025 and $377485.0 in Q1 2025.